1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
China Shineway Pharmaceutical Group Limited

China Shineway Pharmaceutical Group Limited

0.91
EUR
0.00
(0.00%)
687.71MMarket Cap
Mar 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.64
2.7
2.48
2.41
2.32
3.15
3.47
3.51
4.27
5.23
5.98
5
4.15
- -
Basic EPS, GAAP
0.83
0.85
0.8
0.71
0.55
0.62
0.64
0.39
0.74
0.96
1.28
1.11
1.26
- -
Free Cash Flow per Basic Share
0.31
0.75
0.75
0.76
0.48
0.48
0.35
0.76
0.81
1.3
1.04
1.09
1.29
- -
Dividend per Share
0.32
0.33
0.33
0.32
0.32
0.32
0.32
0.32
0.6
0.32
0.42
0.54
0.47
- -
Book Value per Share
5.36
5.92
6.4
6.8
7.04
6.97
6.99
7.01
7.14
7.72
9.31
9.88
10.67
10.67
Tangible Book Value per Share
5.24
5.77
5.74
6.19
6.47
6.43
6.49
6.84
6.86
7.46
9.05
9.63
10.43
10.43
Basic Weighted Avg Shares
827
827
827
827
827
816
781
756
755
755
755
755
755
755
Sales/Revenue/Turnover
2,187
2,229
2,055
1,993
1,920
2,570
2,706
2,656
3,224
3,951
4,517
3,778
3,135
- -
Operating Margin (%)
35.39
33.64
33.55
29.27
21.26
19.23
17.61
16.17
16.79
18.29
21.6
22.3
22.89
- -
Depreciation Expense
102
148
166
195
199
202
205
208
182
186
60
69
71
- -
Net Income, GAAP
684
705
658
589
452
506
503
295
557
723
970
840
950
- -
Effective Tax Rate (%)
20.47
18.41
17.49
15.25
23.18
24.4
21.72
25.31
22.7
21.18
21.83
26.68
25.16
- -
Profit Margin (%)
31.26
31.62
32.02
29.56
23.52
19.68
18.59
11.11
17.27
18.3
21.47
22.24
30.3
- -
Working Capital
2,697
3,064
3,139
3,578
3,851
3,873
4,025
4,324
4,601
5,117
5,721
6,149
6,794
6,794
LT Debt
- -
- -
- -
- -
- -
- -
1
15
7
1
- -
8
1
1
Total Equity
4,430
4,893
5,296
5,627
5,821
5,766
5,777
5,794
5,901
6,383
7,035
7,467
8,062
8,062
Return on Invested Capital (%)
13.72
12.23
11.03
9.09
5.46
6.42
5.62
2.31
6.77
9
10.88
8.02
6.27
- -
Return on Capital (%)
15.38
14.34
12.67
10.79
7.89
8.73
8.46
4.97
9.22
11.75
14.16
11.15
11.77
- -
Return on Common Equity (%)
16.23
15.12
12.91
10.79
7.89
8.73
8.72
5.1
9.52
11.77
14.45
11.59
12.23
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
338
309
334
LT Borrowings
- -
28
- -
LT Finance Leases
8
4
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
755
755
755
Market Capitalization
6,715
5,261
5,650

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
8,599
8,953
9,304
Cash, Cash Equivalents & STI
6,490
6,961
7,566
Accounts Receivable, Net
908
916
806
Inventories
813
722
691
Total Current Liabilities
2,450
2,428
2,510
Payables & Accruals
- -
- -
- -
ST Debt
338
309
334
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.36%
6.87%
7.97%
Free Cash Flow
11.15%
14.09%
18.36%
Net Income, GAAP
8.87%
30.48%
13.08%
Sales/Revenue/Turnover
5.55%
4.98%
-17.01%
Total Cash Common Dividend
- -
17.57%
-12.96%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
4,517
2024
- -
- -
3,778
2025
- -
- -
3,135

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1.28
2024
- -
- -
1.11
2025
- -
- -
1.26

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.42
2024
- -
- -
0.54
2025
- -
- -
0.47

Company Description

Company Profile APIChatGPT
CEO
Zhenjiang Li
Full Time Employees
2,822
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Luan Cheng District Shijiazhuang China 051430
IPO Date
Dec 2, 2004
Website
shineway.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
China Shineway Pharmaceutical Group Limited, an investment holding company listed on the Hong Kong Stock Exchange under ticker 2877.HK (OTCPK: CSWYF), engages in the research, development, manufacture and trade of modern Chinese pharmaceutical products primarily in the People's Republic of China and Hong Kong. Founded in 2002 and headquartered in Shijiazhuang, Hebei Province, China, the company specializes in traditional Chinese medicines across various dosage forms, including injections such as Qing Kai Ling Injection, Shen Mai Injection, Shu Xue Ning Injection, Shuanghuanglian Injection, Dengzhanhua Su Injection and Yinzhi Huang Injection; soft capsules such as Wu Fu Xin Nao Qing Soft Capsule and Qing Kai Ling Soft Capsule; granules such as Chuanxiong Compressed Granules and Huamoyan Granule; traditional Chinese medicine formula granules; tablets such as Compound Licorice Tablet; oral liquids, pills and powders targeting therapeutic areas like respiratory system diseases, cardio-cerebrovascular conditions, nervous system disorders, digestive system diseases, orthopedics, pediatrics and body strengthening medications. The company operates through pharmaceuticals, healthcare products and research and development segments, with injections generating the majority of revenue, and maintains a diversified sales model involving direct sales to hospitals and clinics, partnerships with distributors and retail pharmacies, and exports contributing around 15% of total revenue. In recent developments, the group reported record revenue of RMB 4.2 billion for the year ended December 31, 2023, up 25% year-over-year, driven by strong sales of core products accounting for 70% of revenue; invested approximately RMB 600 million in R&D in 2024, a 12% increase, yielding new products like a novel herbal extract that boosted Q1 2024 sales by 15%; entered three strategic alliances in 2024 to expand research capabilities, including co-development of a new drug projected to generate over RMB 200 million in revenue by year-end; successfully won bids for eight key products in the National Procurement Alliance of Proprietary Chinese Medicine centralized procurements; and acquired 100% equity interest in Shineway-related entity as announced in its 2024 annual results on March 28, 2025.

Company News

Company News APIChatGPT

  • defenseworld.net

    China Shineway Pharmaceutical Group Limited (OTCMKTS:CSWYY) Stock Short Interest Rises 213.8%